A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Phase 1 Completed 19 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

Timeline

Start: 2017-02-03
Primary completion: 2019-06-20
Completion: 2020-03-17

Publications

Doi T, Yamamoto N, Naito Y, Kuboki Y, Koyama T, Piao Y, Tsujimoto N, Asou H, Inoue K, Kondo S. Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Med. 2021 Oct;10(19):6579-6589. doi: 10.1002/cam4.4110. Epub 2021 Sep 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Merestinib	Small molecule	80 mg	Oral
Subject	Merestinib	Small molecule	120 mg	Oral
Background	Cisplatin	Other / unclassified	25 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Summary

Timeline

Publications

Drugs

Indications